SCP Investment’s Spyre Therapeutics SYRE Stock Holding History

SCP Investment’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-6,245	Closed	-$1.65M	–	60
2018 Q2	$1.65M	Buy	+6,245	New	+$1.54M	0.82%	43

Other funds holding SYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCP Investment's SYRE Position: Q3 2018 in Review

SCP Investment sold out of Spyre Therapeutics (SYRE) in Q3 2018, closing a stake of 6,245 shares — an estimated $1.65M sold.

SCP Investment first reported a position in SYRE in Q2 2018 and held it in 1 quarter. The position peaked at $1.65M in Q2 2018. 59 funds tracked by Wall St. Rank hold SYRE as of Q3 2018.

SCP Investment reported no remaining Spyre Therapeutics position as of Q3 2018 after selling out during the quarter.
SCP Investment sold 6,245 Spyre Therapeutics shares in Q3 2018, an estimated $1.65M.
SCP Investment first reported a position in Spyre Therapeutics in Q2 2018 and held it in 1 quarter.
SCP Investment's Spyre Therapeutics position peaked at $1.65M in Q2 2018.
59 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2018.

Based on SCP Investment's 13F filing for Q3 2018, filed 13 Nov 2018.